Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | MMP2 | P08253 | 12/20 | 0.70 |
| ▸ | MMP9 | P14780 | 12/20 | 0.70 |
| ▸ | MMP14 | P50281 | 12/20 | 0.70 |
| ▸ | MMP8 | P22894 | 11/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MMP11 | P24347 | 2/20 | 0.67 |
| ▸ | ECE1 | P42892 | 1/20 | 0.66 |
| ▸ | MMP7 | P09237 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5399966 | 0.98 | NMBR (0.71) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL29472048 | 0.96 | NMBR (0.73) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL1711383 | 0.96 | NMBR (0.73) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL5381814 | 0.96 | NMBR (0.73) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL5379426 | 0.93 | MMP2 (0.66) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL14595066 | 0.92 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL5384805 | 0.90 | CCKBR (0.66) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL14595064 | 0.90 | NMBR (0.74) | NMBRMAPTGAAHTTMMP2 | |
| SCHEMBL31326046 | 0.90 | NMBR (0.74) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL5380441 | 0.90 | NMBR (0.74) | NMBRMAPTGAAHTTMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | NMBR 4026/4885MAPT 4430/4885GAA 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.